Pfizer SWOT Analysis

Abstract

Starting from 2020, the world has been changed by the COVID-19 pandemic, a highly contagious virus that hit the world with many lives lost and the economy disrupted. This article analyzed Pfizer as the global leading pharmaceutical company, and a giant in biopharma, which demonstrated huge success in the pandemic with its famous COVID-19 vaccine “Comirnaty” and its oral anti-COVID drug, “Paxlovid”. The SWOT analysis helped to better understand Pfizer’s business position and its strength, weakness, opportunities, and threats. Thus we can have a more comprehensive view of Pfizer's business and its future potential. The analysis revealed that although Pfizer has taken some advantages during the pandemic with its bold moves and became the No.1 biopharma company in the world, it’s also facing many challenges, including its weak portfolio, slow R&D, and supply problems. However, we still believe Pfizer is striving to evolve into a more competitive biopharma leader with its continuous focus on science, bold moves, new culture to drive excellence, and new agile way of working.